Biotech Values

[DewDiligence]

(ALNY)—How big is the “residual” hypertension market?

https://www.businesswire.com/news/home/20190311005243/en

Alnylam Pharmaceuticals…announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom to initiate a Phase 1 study of ALN-AGT, an investigational RNAi therapeutic targeting angiotensinogen (AGT) for the treatment of hypertension in high unmet need populations, including patients with resistant or refractory hypertension, chronic kidney disease or heart failure. The Company plans to initiate a Phase 1 study in mid-2019, upon obtaining MHRA approval.

There are dozens of generic hypertension drugs available worldwide using various MoAs, but there could be a niche for a product like this—if it works. (No position.)